• Business

    AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports – Reuters

    AnyFans Posted on

    By Reuters

    Copyright reuters

    AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports - Reuters

    Oct 6 (Reuters) – AstraZeneca (AZN.L), opens new tab has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.

    The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said.

    Reuters could not immediately confirm the FT report.

    Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich

    Purchase Licensing Rights